4]/fi: ~) : XmwCWmk )=1%;!XKX%} 8p[y^ { D-}xN ^j?1rX8T_ t,ANxUN=FAFx )LD` ji)l~j]ji YF xHxpfKx* ?iF9 q%x^e3%Hqq%Iq^)I5q- cG]GS 5MYz2p5 z^j%3,}^L&} Q\U3\,nQsS,QQQ yBlbIzrB$+r 4WIfW@H: obbbc]bbd. 7+P /7czN9c @] u=w 8i9 6W[S^ ftfv29m9 J, /Lb- uhHeY &5p Rj-]-9h-+ (g ={#p !retv L||.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/,i2(mut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.